.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The WOMAN trial randomized more than 20,000 women with postpartum hemorrhage to tranexamic acid or placebo. Overall, tranexamic acid did not significantly reduce the composite of all-cause mortality or hysterectomy, but it significantly reduced death due to bleeding, particularly when treatment was given within 3 hours of childbirth. No increase in thromboembolic events was identified. The practical implication for obstetric teams is that timing matters: tranexamic acid is most useful as an early component of a broader postpartum-hemorrhage response rather than as a late rescue measure. Clinicians still need simultaneous uterotonic therapy, uterine assessment, blood-product support when indicated and rapid identification of trauma, retained tissue or coagulopathy. The trial helped move tranexamic acid from a specialist or optional intervention toward a standard evidence-based component of PPH management. It is especially relevant to simulation training because effective response depends on recognition, protocol activation and coordinated multidisciplinary action.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The WOMAN trial randomized more than 20,000 women with postpartum hemorrhage to tranexamic acid or placebo. Overall, tranexamic acid did not significantly reduce the composite of all-cause mortality or hysterectomy, but it significantly reduced death due to bleeding, particularly when treatment was given within 3 hours of childbirth. No increase in thromboembolic events was identified. The practical implication for obstetric teams is that timing matters: tranexamic acid is most useful as an early component of a broader postpartum-hemorrhage response rather than as a late rescue measure. Clinicians still need simultaneous uterotonic therapy, uterine assessment, blood-product support when indicated and rapid identification of trauma, retained tissue or coagulopathy. The trial helped move tranexamic acid from a specialist or optional intervention toward a standard evidence-based component of PPH management. It is especially relevant to simulation training because effective response depends on recognition, protocol activation and coordinated multidisciplinary action.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
